CRISPR gene editing trial seeks to reboot immune system against incurable blood cancer
Disease control
Recruiting now
This early-stage trial is testing a new treatment for multiple myeloma that has returned or stopped responding to standard therapies. Doctors will collect patients' own immune cells, use CRISPR gene-editing technology to reprogram them to attack cancer, then infuse them back into…
Phase: PHASE1 • Sponsor: Thomas Martin, MD • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC